Analysts’ Viewpoint on Global Market Scenario
The global market for diabetes devices is estimated to grow at a rapid pace by 2031. Diabetes devices are used to diagnose and monitor blood glucose level in a diabetic patient’s body. Increase in demand for minimally invasive devices has prompted companies to launch patient-convenient blood glucose monitoring devices. Surge in patient pool suffering from diabetes has led to rise in the demand for diabetes lancet devices and diabetes care devices. The geriatric population is highly susceptible to diabetes, which has propelled the demand for diabetes tracker devices. Furthermore, initiatives taken by governments to spread awareness about diabetes devices have fueled the global diabetes care devices market size. Improvement in healthcare infrastructure and economic growth are also propelling the diabetes devices market demand. However, less awareness about the usage of devices in remote and underdeveloped regions, long registration processes, and reimbursement issues are likely to restrain the global market. Nevertheless, companies are focusing on minimizing the cost of diabetes tracker devices, which is likely to increase the demand for these devices.
Diabetes is a global issue affecting millions of people every year. In the last decade, type 1 diabetes has been one of the major healthcare concerns across the world. Countries such as the U.S., China, the U.K., and Germany have witnessed increasing rates of type 1 diabetes incidence. Type 1 diabetes is a form of autoimmune disease that occurs in children and adults, in which the pancreas stops producing insulin. The surge in the incidence of type 1 diabetes among children is one of the major healthcare concerns. According to IDF, in 2015, Europe had 140,000 children (0-14 years) with type-1 diabetes, and 21,600 new cases are diagnosed every year. Type-1 diabetes patients primarily use insulin pens or insulin pumps. Insulin pumps are more expensive than other insulin delivery devices. However, according to diabetes device market trends, the adoption of insulin pumps is increasing at a steady pace in developing and developed countries.
The COVID-19 pandemic has had a negative effect on the global market. The pandemic resulted in stock market turbulence, stringent border controls, and countrywide lockdowns, all taking their toll on various sectors. The pandemic has significantly strained hospital resources, including medical equipment and healthcare professionals. The supply chain of diabetes devices has been hampered, which has negatively affected the diabetes device market. However, diabetes is a chronic disease, and governments have sought to maintain a regular supply of diabetes devices. A large population worked from home during the lockdown, and numerous patients used remote monitoring devices for diabetics. People were more focused on their diet to control diabetes naturally by regulating their food. These factors hampered the market for diabetes devices.
In terms of product type, the global diabetes devices market has been classified into glucose monitoring devices, insulin delivery devices, diabetes monitoring software, and artificial pancreas systems. The glucose monitoring devices segment has been segregated into self-monitoring blood glucose meters, blood glucose testing strips, lancets, and continuous glucose monitoring meters. The insulin delivery devices market segment has been split into insulin syringes, insulin pens, and insulin pumps. The glucose monitoring devices segment dominated the global market for diabetes care devices in 2021. The trend is projected to continue during the forecast period. The wide availability of diabetes tracker devices with advanced sensors for the detection of blood sugar levels is a major driver of the segment. Moreover, the usage of wireless technology in continuous glucose monitoring (CGM) for transmitting glucose readings collected from the interstitial fluid between the patient’s skin cells has become an important tool for diabetes monitoring devices.
Based on distribution channels, the global diabetes care devices market has been divided into hospital pharmacies, retail pharmacies, online pharmacies, and diabetes clinics/centers. Hospital pharmacies is projected to be a highly attractive segment during the forecast period. A high prevalence of type 2 and 1 diabetes is anticipated to increase hospital visits. Furthermore, the prevalence of diabetes among hospitalized patients is a major factor that drives the demand for diabetes devices at hospital pharmacies. The hospital pharmacies segment is likely to dominate the diabetes devices market during the forecast period. An increase in investment in R&D and a promising pipeline of artificial pancreas systems are anticipated to fuel the hospital pharmacies segment.
North America accounted for a major share of the global diabetes devices market in 2021. This is ascribed to the large diabetes population, higher awareness, significant healthcare spending in the overall national budget, early availability of advanced technologies, and higher penetration of healthcare services across the country. The U.S. is a major market for diabetes devices in North America. Factors such as the aging population, highly structured healthcare industry, and availability of well-defined reimbursement policies from public and private health insurance firms augment the diabetes care devices market in the U.S. A report published in 2022 stated that the U.S. accounted for 37.3 million people who have diabetes, which is 11.3% of the population of the country. Around 28.7 million people have been diagnosed with diabetes. Among these, 8.5 million people who have diabetes have not been diagnosed and do not know they have it. Diabetes is the leading cause of kidney failure, blindness, and amputations in the U.S.
The market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period due to the rise in the prevalence of infectious diseases. An increase in the geriatric population, a surge in healthcare expenditure, and a rise in patient awareness about diabetes devices are fueling the market in the region. Countries such as China and India are expected to dominate the diabetes devices business in the region in the next few years. Asia Pacific is a relatively untapped market than developed regions. Hence, the region presents better growth opportunities in this market. China and India are the most populous countries in the world and have the maximum number of diabetes patients. According to the International Diabetes Federation 2017, China has the largest number of people with diabetes aged between 20 and 79 years.
The diabetes devices market report includes vital information about leading players in the global market. Companies are adopting product launches, divestiture, mergers & acquisitions, and partnership strategies to enhance their market share. Medtronic, Novo Nordisk A/S, Sanofi, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Tandem Diabetes Care, Inc., Abbott Laboratories, Cellnovo, Insulet Corporation, LifeScan, Inc., and Owen Mumford Ltd. are the prominent players operating in the global market.
Each of these players has been profiled in the diabetes care devices market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 50.5 Bn |
|
Market Forecast Value in 2031 |
More than US$ 90.2 Bn |
|
Growth Rate (CAGR) for 2022–2031 |
6.0% |
|
Forecast Period |
2022-2031 |
|
Historical Data Available for |
2017-2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional-level analysis. Moreover, the qualitative analysis includes drivers, restraints, opportunities, key trends, and a parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global market was valued at US$ 50.5 Bn in 2021
The global market is projected to reach more than US$ 90.2 Bn by 2031
The global market is anticipated to grow at a CAGR of 6.0% from 2022 to 2031
Rise in prevalence of diabetes and increase in adoption of insulin pumps among type 1 diabetes patients are driving the global market
North America is expected to account for a major share of the global market for diabetes devices during the forecast period
Medtronic, Novo Nordisk A/S, Sanofi, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Tandem Diabetes Care, Inc., Abbott Laboratories, Cellnovo, Insulet Corporation, LifeScan, Inc., and Owen Mumford Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Diabetes Devices Market
4. Market Overview
4.1. Introduction
4.1.1. Product Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Diabetes Devices Market Analysis and Forecast, 2017-2031
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Technological Advancements
5.2. Value Chain Analysis
5.3. Estimated Number of People with Diabetes Worldwide and Per Region (Age 20-79 years)
5.4. Emerging Technologies in Diabetes Management
5.5. COVID-19 Impact Analysis
6. Global Diabetes Devices Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product Type, 2017-2031
6.3.1. Glucose Monitoring Devices
6.3.1.1. Self-monitoring Blood Glucose Meters
6.3.1.2. Blood Glucose Testing Strips
6.3.1.3. Lancets
6.3.1.4. Continuous Glucose Monitoring Meters
6.3.2. Insulin Delivery Devices
6.3.2.1. Insulin Syringes
6.3.2.2. Insulin Pens
6.3.2.3. Insulin Pumps
6.3.3. Diabetes Management Software
6.3.4. Artificial Pancreas System
6.4. Market Attractiveness Analysis, by Product Type
7. Global Diabetes Devices Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2017-2031
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.3.4. Diabetes Clinics/Centers
7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Diabetes Devices Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Diabetes Devices Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Product Type, 2017-2031
9.2.1. Glucose Monitoring Devices
9.2.1.1. Self-monitoring Blood Glucose Meters
9.2.1.2. Blood Glucose Testing Strips
9.2.1.3. Lancets
9.2.1.4. Continuous Glucose Monitoring Meters
9.2.2. Insulin Delivery Devices
9.2.2.1. Insulin Syringes
9.2.2.2. Insulin Pens
9.2.2.3. Insulin Pumps
9.2.3. Diabetes Management Software
9.2.4. Artificial Pancreas System
9.3. Market Value Forecast, by Distribution Channel, 2017-2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.3.4. Diabetes Clinics/Centers
9.4. Market Value Forecast, by Country, 2017-2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Product Type
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Diabetes Devices Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product Type, 2017-2031
10.2.1. Glucose Monitoring Devices
10.2.1.1. Self-monitoring Blood Glucose Meters
10.2.1.2. Blood Glucose Testing Strips
10.2.1.3. Lancets
10.2.1.4. Continuous Glucose Monitoring Meters
10.2.2. Insulin Delivery Devices
10.2.2.1. Insulin Syringes
10.2.2.2. Insulin Pens
10.2.2.3. Insulin Pumps
10.2.3. Diabetes Management Software
10.2.4. Artificial Pancreas System
10.3. Market Value Forecast, by Distribution Channel, 2017-2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.3.4. Diabetes Clinics/Centers
10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Product Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Diabetes Devices Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product Type, 2017-2031
11.2.1. Glucose Monitoring Devices
11.2.1.1. Self-monitoring Blood Glucose Meters
11.2.1.2. Blood Glucose Testing Strips
11.2.1.3. Lancets
11.2.1.4. Continuous Glucose Monitoring Meters
11.2.2. Insulin Delivery Devices
11.2.2.1. Insulin Syringes
11.2.2.2. Insulin Pens
11.2.2.3. Insulin Pumps
11.2.3. Diabetes Management Software
11.2.4. Artificial Pancreas System
11.3. Market Value Forecast, by Distribution Channel, 2017-2031
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.3.4. Diabetes Clinics/Centers
11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Product Type
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Diabetes Devices Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product Type, 2017-2031
12.2.1. Glucose Monitoring Devices
12.2.1.1. Self-monitoring Blood Glucose Meters
12.2.1.2. Blood Glucose Testing Strips
12.2.1.3. Lancets
12.2.1.4. Continuous Glucose Monitoring Meters
12.2.2. Insulin Delivery Devices
12.2.2.1. Insulin Syringes
12.2.2.2. Insulin Pens
12.2.2.3. Insulin Pumps
12.2.3. Diabetes Management Software
12.2.4. Artificial Pancreas System
12.3. Market Value Forecast, by Distribution Channel, 2017-2031
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.3.4. Diabetes Clinics/Centers
12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Product Type
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Diabetes Devices Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Type, 2017-2031
13.2.1. Glucose Monitoring Devices
13.2.1.1. Self-monitoring Blood Glucose Meters
13.2.1.2. Blood Glucose Testing Strips
13.2.1.3. Lancets
13.2.1.4. Continuous Glucose Monitoring Meters
13.2.2. Insulin Delivery Devices
13.2.2.1. Insulin Syringes
13.2.2.2. Insulin Pens
13.2.2.3. Insulin Pumps
13.2.3. Diabetes Management Software
13.2.4. Artificial Pancreas System
13.3. Market Value Forecast, by Distribution Channel, 2017-2031
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.3.4. Diabetes Clinics/Centers
13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Product Type
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2021
14.3. Company Profiles
14.3.1. Medtronic
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Strategic Overview
14.3.2. Novo Nordisk A/S
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Strategic Overview
14.3.3. Sanofi
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Strategic Overview
14.3.4. Eli Lilly and Company
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Strategic Overview
14.3.5. F. Hoffmann-La Roche Ltd.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Strategic Overview
14.3.6. Becton Dickinson and Company
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Strategic Overview
14.3.7. Tandem Diabetes Care, Inc.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Strategic Overview
14.3.8. Abbott Laboratories
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Strategic Overview
14.3.9. Cellnovo
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Strategic Overview
14.3.10. Insulet Corporation
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Strategic Overview
14.3.11. LifeScan, Inc.
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Product Portfolio
14.3.11.3. SWOT Analysis
14.3.11.4. Strategic Overview
14.3.12. Owen Mumford Ltd.
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Product Portfolio
14.3.12.3. SWOT Analysis
14.3.12.4. Strategic Overview
List of Tables
Table 01: Global Diabetes Devices Market Size (US$ Mn) Forecast, by Product type, 2017-2031
Table 02: Global Diabetes Devices Market Size (US$ Mn) Forecast, by Product Type - Glucose Monitoring Devices 2017-2031
Table 03: Global Diabetes Devices Market Size (US$ Mn) Forecast, by Product Type - Insulin Delivery Devices, 2017-2031
Table 04: Global Diabetes Devices Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 05: Global Insulin Delivery Devices Market Size (US$ Mn) Forecast, by Region, 2017-2031
Table 06: North America Diabetes Devices Market Size (US$ Mn) Forecast, by Country, 2017-2031
Table 07: North America Diabetes Devices Market Size (US$ Mn) Forecast, by Product Type, 2017-2031
Table 08: North America Diabetes Devices Market Size (US$ Mn) Forecast, by Product Type - Glucose Monitoring Devices 2017-2031
Table 09: North America Diabetes Devices Market Size (US$ Mn) Forecast, by Product Type - Insulin Delivery Devices, 2017-2031
Table 10: North America Diabetes Devices Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 11: Europe Diabetes Devices Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 12: Europe Diabetes Devices Market Size (US$ Mn) Forecast, by Product Type, 2017-2031
Table 13: Europe Diabetes Devices Market Size (US$ Mn) Forecast, by Product Type - Glucose Monitoring Devices, 2017-2031
Table 14: Europe Diabetes Devices Market Size (US$ Mn) Forecast, by Product Type - Insulin Delivery Devices, 2017-2031
Table 15: Europe Diabetes Devices Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 16: Asia Pacific Diabetes Devices Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Asia Pacific Diabetes Devices Market Size (US$ Mn) Forecast, by Product Type, 2017-2031
Table 18: Asia Pacific Diabetes Devices Market Size (US$ Mn) Forecast, by Glucose Monitoring Devices, 2017-2031
Table 19: Asia Pacific Diabetes Devices Market Size (US$ Mn) Forecast, by Insulin Delivery Devices, 2017-2031
Table 20: Asia Pacific Diabetes Devices Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 21: Latin America Diabetes Devices Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Latin America Diabetes Devices Market Size (US$ Mn) Forecast, by Product Type, 2017-2031
Table 23: Latin America Diabetes Devices Market Size (US$ Mn) Forecast, by Glucose Monitoring Devices, 2017-2031
Table 24: Latin America Diabetes Devices Market Size (US$ Mn) Forecast, by Insulin Delivery Devices, 2017-2031
Table 25: Latin America Diabetes Devices Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 26: Middle East & Africa Diabetes Devices Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 27: Middle East & Africa Market Size (US$ Mn) Forecast, by Product Type, 2017-2031
Table 28: Middle East & Africa Diabetes Devices Market Size (US$ Mn) Forecast, by Glucose Monitoring Devices, 2017-2031
Table 29: Middle East & Africa Diabetes Devices Market Size (US$ Mn) Forecast, by Insulin Delivery Devices, 2017-2031
Table 30: Middle East & Africa Diabetes Devices Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
List of Figures
Figure 01: Global Diabetes Devices Market, by Product, Market Size (US$ Mn), 2021 (A)
Figure 02: Global Diabetes Devices Market, by Distribution Channel, Market Share, 2021 (A)
Figure 03: Global Diabetes Devices Market Size (US$ Mn) Forecast, 2017-2031
Figure 04: Company Revenue Share (1)
Figure 05: Company Revenue Share (2)
Figure 06: Estimated Number of People with Diabetes Worldwide and Per Region (Age 20-79 years)
Figure 07: Global Diabetes Devices Market Value Share, by Product Type, 2021 and 2025
Figure 08: Global Diabetes Devices Market Attractiveness Analysis, by Product Type, 2022-2031
Figure 09: Global Diabetes Devices Market Value Share, by Glucose Monitoring Devices, 2021 and 2031
Figure 10: Global America Diabetes Devices Market Value Share, by Insulin Delivery Devices, 2021 and 2031
Figure 11: Global Diabetes Devices Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Glucose Monitoring Devices, 2017-2031
Figure 12: Global Diabetes Devices Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Insulin Delivery Devices, 2017-2031
Figure 13: Global Diabetes Devices Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Diabetes Monitoring Software, 2017-2031
Figure 14: Global Diabetes Devices Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Artificial Pancreas System, 2017-2031
Figure 15: Global Diabetes Devices Market Value Share, by Distribution Channel, 2021 and 2025
Figure16: Global Diabetes Devices Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 17: Global Diabetes Devices Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017-2031
Figure 18: Global Diabetes Devices Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017-2031
Figure 19: Global Diabetes Devices Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2017-2031
Figure 20: Global Diabetes Devices Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Diabetes Clinics/ Centers, 2017-2031
Figure 21: Global Diabetes Device Market Scenario, by Country (1/1)
Figure 22: Global Diabetes Devices Market Value Share Analysis, by Region, 2021 and 2025
Figure 23: Global Diabetes Devices Market Attractiveness Analysis, by Region, 2022-2031
Figure 24: North America Diabetes Devices Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 25: North America Diabetes Devices Market Attractiveness Analysis, by Country, 2022-2031
Figure 26: North America Diabetes Devices Market Value Share Analysis, by Country, 2021 and 2031
Figure 27: North America Diabetes Devices Market Value Share, by Product Type, 2021 and 2031
Figure 28: North America Diabetes Devices Market Attractiveness Analysis, by Product Type, 2022-2031
Figure 29: North America Diabetes Devices Market Value Share, by Glucose Monitoring Devices, 2021 and 2031
Figure 30: North America Diabetes Devices Market Value Share, by Insulin Delivery Devices, 2021 and 2031
Figure 31: North America Diabetes Devices Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Fig 32: North America Diabetes Devices Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 33: Europe Diabetes Devices Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 34: Europe Diabetes Devices Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 35: Europe Diabetes Devices Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 36: Europe Diabetes Devices Market Value Share, by Product Type, 2021 and 2031
Figure 37: Europe Diabetes Devices Market Attractiveness Analysis, by Product Type, 2017-2031
Figure 38: Europe Diabetes Devices Market Value Share, by Glucose Monitoring Devices, 2021 and 2031
Figure 39: Europe Diabetes Devices Market Value Share, by Insulin Delivery Devices, 2017-2031
Figure 40: Europe Diabetes Devices Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 41: Europe Diabetes Devices Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 42: Asia Pacific Diabetes Devices Market Size (US$ Mn) Forecast, and Y-o-Y Growth (%) Forecast, by region, 2017-2031
Figure 43: Asia Pacific Diabetes Devices Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 44: Asia Pacific Diabetes Devices Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 45: Asia Pacific Diabetes Devices Market Value Share Analysis, by Product Type, 2021 and 2031
Figure 46: Asia Pacific Diabetes Devices Market Attractiveness Analysis, by Product Type, 2022-2031
Figure 47: Asia Pacific Diabetes Devices Market Value Share, by Glucose Monitoring Devices, 2021 and 2031
Figure 48: Asia Pacific Diabetes Devices Market Value Share, by Insulin Delivery Devices, 2017-2031
Figure 48: Asia Pacific Diabetes Devices Market Value Share, by Insulin Delivery Devices, 2017-2031
Figure 49: Asia Pacific Diabetes Devices Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 50: Asia Pacific Diabetes Devices Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 51: Latin America Diabetes Devices Market Size (US$ Mn) Forecast, and Y-o-Y Growth (%) Forecast, by region, 2017-2031
Figure 52: Latin America Diabetes Devices Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 53: Latin America Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 54: Latin America Market Value Share Analysis, by Product Type, 2021 and 2031
Figure 55: Latin America Diabetes Devices Market Attractiveness Analysis, by Product Type, 2022-2031
Figure 56: Latin America Diabetes Devices Market Value Share, by Glucose Monitoring Devices, 2021 and 2031
Figure 57: Latin America Diabetes Devices Market Value Share, by Insulin Delivery Devices, 2017-2031
Figure 58: Latin America Diabetes Devices Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 59: Latin America Diabetes Devices Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 60: Middle East & Africa Diabetes Devices Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast 2017-2031
Figure 61: Middle East & Africa Diabetes Devices Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 62: Middle East & Africa Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 63: Middle East & Africa Market Value Share Analysis, by Product Type, 2022-2031
Figure 64: Middle Diabetes Devices Market Attractiveness Analysis, by Product Type, 2022-2031
Figure 65: Middle East & Africa Diabetes Devices Market Value Share, by Glucose Monitoring Devices, 2021 and 2031
Figure 66: Middle East & Africa Diabetes Devices Market Value Share, by Insulin Delivery Devices, 2017-2031
Figure 67: Middle East & Africa Diabetes Devices Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 68: Middle East & Africa Diabetes Devices Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 69: Medtronic, Revenue (US$ Bn) & Y-o-Y Growth (%), 2017-2021
Figure 70: Medtronic, R&D Intensity and Sales & Marketing Intensity (%) - Company Level or Segment Level, 2017-2021
Figure 71: Medtronic, Breakdown of Net Sales, by Region 2017
Figure 72: Medtronic, Breakdown of Net Sales, by Business Segments, 2017
Figure 73: Novo Nordisk A/S, Revenue (US$ Bn) & Y-o-Y Growth (%), 2017-2021
Figure 74: Novo Nordisk A/S, R&D Intensity and Sales & Marketing Intensity (%), 2017-2021
Figure 75: Novo Nordisk A/S, Breakdown of Net Sales, by Region 2021
Figure 76: Novo Nordisk A/S, Breakdown of Net Sales, by Business Segments, 2021
Figure 77: Sanofi, Revenue (US$ Bn) & Y-o-Y Growth (%), 2017-2021
Figure 78: Sanofi, R&D Intensity and Sales & Marketing Intensity (US$ Bn), 2017-2021
Figure 79: Sanofi, Breakdown of Net Sales, by Region 2021
Figure 80: Sanofi, Breakdown of Net Sales, by Business Segments, 2021
Figure 81: Eli Lilly and Company, Revenue (US$ Bn) & Y-o-Y Growth (%), 2017-2021
Figure 82: Eli Lilly and Company, R&D Intensity and Sales & Marketing Intensity - Company Level, 2017-2021
Figure 83: Eli Lilly and Company, Breakdown of Net Sales, by Region 2017
Figure 84: Eli Lilly and Company, Breakdown of Net Sales, by Endocrinology Segment, 2021
Figure 85: F. Hoffmann-La Roche Ltd., Revenue (US$ Bn) & Y-o-Y Growth (%), 2017-2021
Figure 86: F. Hoffmann-La Roche Ltd., R&D Intensity (US$ Bn), 2017-2021
Figure 87: F. Hoffmann-La Roche Ltd., Breakdown of Net Sales of Diabetes Care Business Area, by Region 2021
Figure 88: F. Hoffmann-La Roche Ltd., Breakdown of Net Sales, by Diagnostic Division, 2021
Figure 89: Becton, Dickinson and Company, Revenue (US$ Bn) & Y-o-Y Growth (%), 2017-2021
Figure 90: Becton, Dickinson and Company, R&D Expense (US$ Mn), 2017-2021
Figure 91: Becton, Dickinson and Company, Breakdown of Net Sales, by Region 2021
Figure 92: Becton, Dickinson and Company, Breakdown of Net Sales, by BD Medical Business segment, 2021
Figure 93: Tandem Diabetes Care, Inc., Revenue (US$ Mn) & Y-o-Y Growth (%), 2017-2021
Figure 94: Tandem Diabetes Care, Inc., R&D Expense (US$ Mn), 2017-2021
Figure 95: Abbott Laboratories, Revenue (US$ Bn) & Y-o-Y Growth (%), 2017-2021
Figure 96: Abbott Laboratories, R&D Intensity and Sales & Marketing Intensity - Company Level, 2017-2021
Figure 97: Abbott Laboratories, Breakdown of Net Sales, by Region 2021
Figure 98: Abbott Laboratories, Breakdown of Net Sales, by Business Segment, 2021
Figure 99: Cellnovo, Revenue (US$ Mn) & Y-o-Y Growth (%), 2017-2021
Figure 100: Insulet Corporation, Revenue (US$ Mn) & Y-o-Y Growth (%), 2017-2021
Figure 101: Insulet Corporation, R&D Intensity and Sales & Marketing Intensity (US$ Mn) - Company Level, 2017-2021
Figure 102: Insulet Corporation, Breakdown of Net Sales, by Region, 2021
Figure 103: Insulet Corporation, Breakdown of Net Sales, by Business Segments 2021
Figure 104: LifeScan, Inc., Concerned Company Revenue (US$ Bn) & Y-o-Y Growth (%), 2017-2021
Figure 105: LifeScan, Inc., R&D Intensity and Sales & Marketing Intensity - Company Level, 2017-2021
Figure 106: LifeScan, Inc., Breakdown of Net Sales, by Region (Company Level), 2021
Figure 107: LifeScan, Inc., Breakdown of Net Sales, (By Business And Business Segment Level), 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Diabetes Devices Market
